Bivalirudin is superior to heparins alone with bailout GP IIb/IIIa inhibitors in patients with ST-segment elevation myocardial infarction transported emergently for primary percutaneous coronary intervention: a pre-specified analysis from the EUROMAX trial

AIMS: In the HORIZONS trial, in-hospital treatment with bivalirudin reduced bleeding and mortality in primary percutaneous coronary intervention (PCI) compared with heparin and routine glycoprotein IIb/IIIa inhibitors (GPI). It is unknown whether this advantage of bivalirudin is observed in comparis...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Zeymer, Uwe, van 't Hof, Arnoud, Adgey, Jennifer, Nibbe, Lutz, Clemmensen, Peter, Cavallini, Claudio, ten Berg, Jurrien, Coste, Pierre, Huber, Kurt, Deliargyris, Efthymios N., Day, Jonathan, Bernstein, Debra, Goldstein, Patrick, Hamm, Christian, Steg, Philippe Gabriel
Format: Artigo
Jezik:Inglês
Izdano: Oxford University Press 2014
Teme:
FASTTrack Clinical Research
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC4169872/
https://ncbi.nlm.nih.gov/pubmed/24849104
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/eurheartj/ehu214
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items